The rise of Viagra initially drove a surge for pharma, but recent shifts present a murky scenario for investors. Off-patent versions are reducing profits, and continued legal battles add further difficulty to the https://barbaracifo464775.bloggactif.com/42638381/the-blue-pill-and-the-pharmaceutical-industry-a-risky-bet